Skip to content
Companies

Dewpoint Therapeutics

Small-molecule drugs that target biomolecular condensates

Raised to date

$77.2M

of $82.3M offered across 1 Form D filing

Still open
$5.1M
Investors
23
Last filed
Jul 13, 2026

About

Dewpoint Therapeutics, Inc. is a Boston-based clinical-stage biotechnology company and the first founded to apply biomolecular condensate biology to drug discovery. Condensates are membraneless compartments that organize cellular chemistry, and Dewpoint's thesis is that many diseases arise from their dysregulation, opening targets previously considered undruggable. The company discovers small-molecule condensate modulators, or c-mods, using ERSAi, a proprietary AI-enabled discovery platform that codifies relationships between condensates, human disease, and chemistry. Its pipeline spans oncology, neurodegeneration, cardiopulmonary, and metabolic disease, with research sites in Boston and Dresden, Germany, and it has raised roughly $287 million across Series A, B, and C rounds.

A drug modality built entirely around biomolecular condensates rather than single protein targets, paired with the ERSAi AI-enabled discovery platform, allowing it to pursue targets such as beta-catenin, MYC, and TDP-43 that have resisted conventional small-molecule approaches.

Funding

  • EquityFiled Jul 13, 2026Form D/A
    $77.2M/ $82.3M

Product

Condensate modulator (c-mod) pipeline

Clinical-stage small-molecule therapeutics

A portfolio of small-molecule condensate modulators discovered on the ERSAi platform, led by DPTX3186, a beta-catenin condensate modulator in Phase 1/2 for gastric cancer with FDA fast track and orphan drug designations, alongside an oral MYC modulator enrolling patients in solid tumors and a TDP-43 development candidate for ALS.

  • ERSAi discovery platform combining high-resolution condensate biology, chemistry, proprietary datasets, and AI
  • DPTX3186, a beta-catenin condensate modulator in Phase 1/2 for gastric cancer, with FDA fast track and orphan drug designation and first patient dosed in early 2026
  • Oral MYC condensate modulator in Phase 1/2, enrolling patients in solid tumors

Built for

Patients with condensate-driven diseases - initially gastric cancer and other solid tumors, ALS and related neurodegeneration, dilated cardiomyopathy, and insulin resistance - reached through oncologists and neurologists, plus large pharmaceutical partners who license programs off the platform.

People on file